



Screening Solutions

The CRC screening gap




Colorectal cancer (CRC) is highly treatable if caught early, but it remains the second leading cause of cancer-related deaths in the U.S. Over 75% of the individuals who die from CRC are not up to date with their screening. Yet, 1 out of 3 eligible Americans do not complete the recommended screening in part because they find the available options—colonoscopy and stool tests—unpleasant or inconvenient.

Cancer screening with a simple blood draw

The Shield test from Guardant Health is the first blood test approved by the FDA as a primary screening option for CRC. It allows patients to overcome the barriers associated with other methods by getting a simple blood draw during a routine healthcare visit. The test detects alterations associated with colorectal cancer in the blood.*

Shield is the result of years of research and development, including collaboration between Guardant and leading health organizations globally. The FDA based its approval on the results of ECLIPSE, a large study published in The New England Journal of Medicine in March 2024, demonstrating the test accuracy for detecting CRC is within range of other guideline-recommended non-invasive screening methods. Shield is available for eligible individuals by prescription through a healthcare provider and meets Medicare coverage.



#2

CRC is the second leading cause of cancer-related deaths.

83%

Shield is 83% accurate in detecting CRC in average-risk adults.

90%

More than 90% of patients who are prescribed the Shield test complete it.

Important Product Information

Shield is indicated for individuals age 45 and older at average risk for colorectal cancer, and results are available in approximately two weeks. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation. Shield is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals. Please visit [ShieldCancerScreen.com](https://www.shieldcancerscreen.com) for complete product information about the Shield test, including full safety information. Precaution: Based on data from clinical studies, Shield has limited detection (55%–65%) of Stage I colorectal cancer and does not detect 87% of precancerous lesions. One out of 10 patients with a negative Shield result may have a precancer that would have been detected by a screening colonoscopy. Shield demonstrated high detection of Stage II, III, and IV colorectal cancer.

<https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html>. Accessed May 8, 2023. 2. Doubeni, C, et al. Gastroenterology. 2019 Jan; 156(1): 63–74.e6. 3. <https://nccrt.org/our-impact/data-and-progress/>. Accessed November 9, 2023. 4. Raymond, V, et al. The American Journal of Gastroenterology 118(10S):p S218, October 2023.

